Medicare to cover early Alzheimer's blood tests starting 2028
H.R. 6130 — ASAP Act · Filed by Vern Buchanan (R-FL) · 202 cosponsors · Introduced Nov 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare law to cover blood-based screening tests for early-stage Alzheimer's disease and related dementias, effective January 1, 2028. The tests must be FDA-cleared, classified, or approved, and include blood tests, genomic sequencing, protein analysis, and related biomarker tests. Medicare will pay for these screenings as a covered benefit.
Why we flagged it
The bill's sole operative mechanism is to add a new category of preventive screening tests to Medicare's covered services. It is a straightforward benefit expansion, not a regulatory change or carve-out.
What the text implies
- The bill grants the Secretary of Health and Human Services broad discretion to define 'equivalent tests' beyond the specified blood tests, potentially expanding coverage to imaging and other biomarker tests not yet developed or validated.
- No payment rate or reimbursement cap is specified in the bill text; actual Medicare payment rates will be set through separate regulatory process, creating uncertainty about cost to the program.
The full analysis lists 4 implications of this text.
Who stands to gain
in vitro diagnostic (IVD) manufacturers producing blood-based biomarker tests; genomic sequencing companies; clinical laboratory service providers